InterStudy Publications, a division of Decision Resources, announces the release of its Competitive Edge Managed Care Directory Fall 2004. This report, which provides comprehensive plan enrollment and contact information, is the first in a series of Competitive Edge reports that now present combined HMO and PPO data and analysis.

"By integrating HMO and PPO data into a single source, we have made it even easier for clients to assess managed care organizations across the nation," said Tammy Lauer, research director for InterStudy. "These studies offer fast, accurate, and complete access to critical managed care performance data."

InterStudy publishes the Competitive Edge series semiannually. The Managed Care Directory is the first of this three-part series on HMOs and PPOs. Part II, The Managed Care Industry Report, analyzes plan growth and characteristics associated with growth in HMOs and PPOs. Part III, The Regional Market Analysis, examines the market structure and dynamics of metropolitan markets served by HMOs and PPOs. Competitive Edge is the result of InterStudy's longest standing research program and is built on the industry's most reliable research methods.

About InterStudy Publications

InterStudy Publications, a division of Decision Resources, offers data, directories, and analyses of the ever-evolving managed care industry. InterStudy tracks changes and trends in HMO and PPO services, enrollment, and profitability. Visit InterStudy Publications at

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Contact:    Frank Sama    InterStudy Publications    781-296-2553 

SOURCE: InterStudy Publications

CONTACT: Frank Sama of InterStudy Publications, +1-781-296-2553,

Analyst Available to Comment on the Withdrawal of Merck's Vioxx from the Market

View Now